Virtual Library
Start Your Search
H. Jiang
Author of
-
+
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
-
+
80P - Understanding the patient perspective of small cell lung cancer (SCLC) (ID 265)
12:30 - 13:00 | Author(s): H. Jiang
- Abstract
Background:
When developing a patient-reported outcomes assessment strategy, empirical evidence based on literature review and therapeutic area experts should be complemented with input directly from patients to reliably reflect the patients’ experiences. Therefore, a set of research activities were initiated to identify, describe, and substantiate concepts that reflect the important and relevant symptoms, treatment-related side effects, and impacts of extensive stage (ES)-SCLC.
Methods:
Twenty-five articles were reviewed, four clinical experts participated in advice meetings and 17 US patients diagnosed with ES-SCLC were interviewed. Trained interviewers used a semi-structured interview guide to elicit information from patients. Interviews were transcribed, coded, and analysed using qualitative data analytic methods.
Results:
Patients’ mean age was 65.2 years (SD = 9.8) and patients self-reported as white (n = 11, 64.7%), black or African American (n = 5, 29.4%), and American Indian or Alaska Native (n = 1, 5.9%). Thirty-one signs/symptoms of ES-SCLC were elicited with fatigue being mentioned by most patients (n = 10). Also, the most frequently reported SCLC symptoms were shortness of breath (n = 6, 35.3%), pain (n = 5, 29.4%), and weight loss (n = 4, 23.5%). Patients also reported numerous ways that their lives were impacted by ES-SCLC (n = 68 concepts), and treatment-related side-effects they experienced (n = 41 concepts). These findings, along with evidence from literature review and clinical experts, showed that shortness of breath, pain, weight loss, cough, fatigue, nausea, paraneoplastic syndromes, haemoptysis, and loss of appetite were reported as signs and symptoms of SCLC in all three research activities.
Conclusions:
This study provides an overview of symptoms, treatment-related side effects, and impacts associated with ES-SCLC from the patient perspective. The results suggest that patients with SCLC have similar key symptoms to patients with non-small cell lung cancer, therefore similar measurement strategies can be applied. Using this evidence, recommendations can be made for ES-SCLC clinical trial outcomes that resonate with primary stakeholders including patients, healthcare providers, regulatory agencies, and payers.
Clinical trial identification:
Not applicable.
Legal entity responsible for the study:
AstraZeneca PLC
Funding:
AstraZeneca
Disclosure:
A. Rydén, H. Jiang, P. Dennis: AstraZeneca: full-time employment and stock ownership. S. Ollis, E. Love, A.L. Shields: Employee of Adelphi Values, which receives payment from pharmaceutical companies to conduct outcomes-based research.
